COVID antibody test in 10 mins: Cipla launches Covi-G for COVID-19 rapid antibody detection
Advertisement
  Mumbai: Drug major, Cipla Limited, today announced that the company signed a licensing agreement with a  Belgium- based firm, Multi G for the distribution of their COVID-19 Rapid Antibody test  kit, across most Emerging markets and Europe.
As part of this agreement, Cipla will be responsible for distribution of the COVID-19  rapid antibody kit that will be manufactured by MultiG. It is marketed under the brand  name 'Covi-G', this was among the earliest Antibody kits to declare CE-compliance  and is awaiting approval by ICH country regulators
  Our comments section is governed by our  Comments Policy . By posting comments at Medical Dialogues you automatically agree with our  Comments Policy ,  Terms And Conditions  and  Privacy Policy .  
      
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.